We are pleased to announce our partnership with the PHARMO Institute, an organization dedicated to developing cutting-edge solutions that support enhanced real world data analytics.
The PHARMO Institute is a European-based globally recognized research organization with a focus on pharmaco-epidemiology, drug utilization, drug safety, and health outcomes and they have direct access to longitudinal anonymized patient level data from the Netherlands. The PHARMO Institute’s services are highly synergistic with Lumanity’s real world evidence (RWE) capabilities, and the two companies share a mission to optimize patient access to therapies with a focus on demonstrating real world safety and effectiveness. Working together the two organizations are now able to offer a global RWE capability with experts based in both the US and the EU.
“This partnership signifies our enthusiasm and dedication to expanding in the RWE space and providing our clients with deeper capabilities and direct access to patient level data,” says Gema Parlange, Global Practice Lead for RWE at Lumanity. “We have a great team of expert ‘Data Luminaries’ across Lumanity, who can ask the right questions, know when and with whom to partner, consider the whole product lifecycle, and understand and embrace regulatory requirements. We look forward to expanding and further amplifying our expertise by working with the knowledgeable RWE experts from PHARMO.”
“Dutch healthcare data are one of the most detailed RWE sources in the world, representative of Western Europe, and with rich primary care data,” adds Prof. Dr. Ron Herings, founder and director of The PHARMO Institute. “I’m very happy that we have found a deeply science-oriented and mission aligned international partner that will enable us, and by extension the Netherlands, to play a much greater role in addressing the global research questions facing researchers.”
Moving forward, Lumanity and The PHARMO Institute will continue to generate evidence of the safety, effectiveness, and value of medicines for the betterment of patient care in the EU, and around the world. We plan to continue to collaborate and expand in the RWE space, addressing global use cases in pharmacoepidemiology, healthcare resource utilization, and outcomes research.
Contact us to learn more about our RWE capabilities and our collaborating with The PHARMO Institute.
